[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anaemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100608120","the-use-of-robot-assisted-magnetically-controlled-capsule-endoscopy-in-patients-with-iron-deficiency-anaemia-100608120",false,"NCT07197424","The Use of Robot Assisted Magnetically Controlled Capsule Endoscopy in Patients With Iron Deficiency Anaemia","Robot Assisted Magnetically Controlled Capsule Endoscopy","Inclusion Criteria:\n\n* Adult patients aged 18 and above\n* Confirmed diagnosis of iron deficiency anaemia (either recent onset or recurrent)\n* No significant cause for iron deficiency anaemia previously identified on upper GI endoscopy, colonoscopy or CT colonography\n* Patients who would either have proceeded directly to small bowel capsule endoscopy (SBCE) or who would have had an initial 'watch and wait' period prior to undergoing SBCE\n\nExclusion Criteria:\n\n* Known or suspected gastrointestinal obstruction, strictures or fistulae\n* Previous abdominal surgery\n* Dysphagia\n* Patients with a pacemaker, defibrillator or other implanted electronic device\n* In vivo retention with medical metal fittings - shunts, plates, stents or clips\n* A history of metal fragments in the eyes or elsewhere in the body\n* Confirmed or possible pregnancy\n* Patients who are not deemed to have capacity according to the Adults with Incapacity Act\n* Patients who are currently part of another research study","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","In this study the investigators will recruit patients who have already had an upper gastrointestinal (GI) tract endoscopy (OGD) and lower GI tract investigations which did not identify the source of iron deficiency anaemia, and who need the small bowel to be investigated. This will comprise both patients who would have proceeded directly to small bowel capsule endoscopy (SBCE) under standard care and also those from whom an initial 'watch and wait' approach may have been adopted before proceeding to SBCE. The investigators propose to investigate these patients during a single patient visit to Leith Community Treatment Centre, Edinburgh, Scotland, with a CE marked robotic capsule system which can examine both the upper GI tract (i.e. the oesophagus and the stomach) and the small bowel in one investigation using a magnetic guided capsule.\n\nThe aim of the study is to compare the findings from OGD with the robotic capsule system and to determine if such a system may safely replace OGD - thus examining the upper GI tract and small bowel for IDA in one less invasive investigation. This has the potential to decrease patient discomfort, stress and anxiety, while also reducing pressure on busy endoscopy departments, helping to ensure that the right patients receive the right investigations in a timely manner.",[26],"Iron Deficiency Anaemia",[28,29,30],"capsule endoscopy","robot assisted magnetically controlled capsule endoscopy","iron deficiency anaemia","RECRUITING","2026-05-13",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2026-05-11",{"date":39,"type":20},"2027-03",{"name":41,"class":42},"University of Edinburgh","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100584049","phase-3-comparing-high-and-low-dose-iron-treatments-for-people-on-peritoneal-dialysis-the-paladin-study-100584049","NCT06884280","Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study","Proactive High Dose Versus Low-dose Reactive Intravenous or Oral Iron in People on Peritoneal Dialysis (PALaDIN) - an Open-label, Feasibility Randomised Study","PALaDIN","Inclusion Criteria:\n\n* Males and females aged ≥18 years.\n* Able to give informed consent\n* Serum ferritin \\\u003C700ug\u002FL\n* Transferrin saturation level \\\u003C40%\n* No intravenous iron for last 4 weeks before randomisation (patients may be pre-identified and included after 4-week washout period)\n* Received maintenance peritoneal dialysis therapy for at least 4 weeks\n* Expected to remain on peritoneal dialysis therapy for duration of study\n\nExclusion Criteria:\n\n* Inadequate dialysis deemed by responsible clinician\n* Probability of need for transfusion within 1 week of enrolment\n* On or received a HIF-PHI in the past 4 weeks\n* Anticipated major surgery that the responsible clinician feels will impact response to treatment\n* Haemochromatosis \u002F haemosiderosis or ALT \\>x3 normal\n* Are deemed to be most suited to best-supportive or end-of-life care at time of screening\n* Women of childbearing potential not using effective means of contraception\n* Have been involved in another medicinal study (CTIMP) within past 4 weeks\n* Known allergy or adverse reaction to oral or intravenous iron preparations\n* CRP \\>50, TSATs \\>40%, SF \\>700 at time of recruitment\n* Active infection, HIV, active Hep B or C\n* Are unable or unwilling to consent to or complete the study procedures",{"count":53,"type":20},30,[55],"PHASE3","Chronic kidney disease affects a significant portion of the UK population, with approximately 3.5 million adults diagnosed. At its most severe stage, end-stage kidney disease, individuals require frequent dialysis treatment. One form of dialysis, known as peritoneal dialysis, involves introducing and removing fluid from the abdominal cavity to help filter out toxins from the body.\n\nThe kidneys are involved in various hormonal processes, including those responsible for producing red blood cells, making anaemia a common consequence of kidney failure. When designing a clinical trial to evaluate the effectiveness of any treatment, it is essential to determine the number of suitable and willing participants, as well as those who can complete all required tests and measurements. Identifying the most appropriate measurement to assess the impact of intravenous iron (iron injected directly into veins) is crucial to ensure that any observed changes are meaningful to people with CKD and their carers. To address these considerations, the investigators will conduct a pilot feasibility trial.\n\nIn this trial, individuals with kidney disease undergoing peritoneal dialysis will be randomly assigned to receive either high-dose or low-dose intravenous iron, or oral iron therapy. Over twelve months, the investigators will monitor their anaemia response, symptoms of kidney disease, quality of life, physical performance (such as the ability to walk for six minutes), and cognitive function. Additionally, the investigators will assess the impact of each intervention on the frequency of blood transfusions, whether those on oral iron require intravenous iron, and any changes in the dosage of erythropoietin-stimulating agents (drugs that increase blood production).",[58,59,60],"Peritoneal Dialysis","Anaemia","Iron Deficiency, Anaemia","2026-05-05",{"date":63,"type":35},"2026-05-06",{"date":65,"type":35},"2025-11-13",{"date":67,"type":20},"2027-10",{"name":69,"class":70},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":78,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100574597","questionnaire-about-risk-factors-of-iron-deficiency-anemia-in-pregnancy-100574597","NCT06761352","Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy","Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy and How to Prevent it","Inclusion Criteria:\n\n* Women aged 18 years or older with established iron deficiency anemia (HB less than 10)\n* established intrauterine pregnancy\n* women want to participate in the study\n\nExclusion Criteria:\n\n* anemia due to other causes\n* recent blood transfusion in the last 3 months\n* women with threatened miscarriage\n* women are known to have pathological blood loss (urinary bleeding or GIT bleeding) 5- history of haematological disorder 6- women used iron in the past 3 months","FEMALE","45 Years",{"count":81,"type":20},200,"OBSERVATIONAL","Anemia in pregnancy,and especially iron deficiency anemia is both a long standing scholarly interest ,the aim of my research to summarise the risk factors of iron deficiency anemia in pregnancy, especially in Egypt as a less developed country,and suggest recommendations about how to prevent it",[26],"NOT_YET_RECRUITING","2025-01-05",{"date":88,"type":35},"2025-01-07",{"date":90,"type":20},"2025-02",{"date":92,"type":20},"2026-01",{"name":94,"class":42},"Assiut University"]